CollPlant Biotechnologies Ltd. Sponsored ADR

CLGN Healthcare Biotechnology

CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024. In the quarter to June 2026, revenue fell 39.7%, EPS grew 32.5% and free cash flow grew 5.08%, each against the same quarter a year earlier.

3.63 0.05 −1.36%
Market cap
$7.0M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
4/9
Altman Z
−16.87
Beneish M
−3.20
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
4 2 5 2 7 6 2 4 — —
P/E ratio
0.00 0.00 0.00 0.00 74.36 0.00 0.00 0.00 8.86 8.86
Altman Z-Score
(16.87) (6.12) 4.04 6.17 15.34 (3.32) (8.15) (6.01) — —
P/S ratio
7.21 80.07 6.29 317.34 10.43 12.09 12.26 3.67 54.76 54.76
P/FCF ratio
0.00 0.00 0.00 0.00 172.59 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(41.05) (19.67) (0.82) 0.35 8.53 (23.31) (23.55) (18.74) (20.65) (47.33)
Beneish M-Score
(3.20) — 27.27 — (2.16) (1.74) 2.18 3.06 0.22 —
P/Operating CF
(5.82) (11.90) (29.38) (28.36) (67.39) (46.45) (17.34) 5.75 (5.03) (5.03)
P/B ratio
2.81 3.06 2.43 2.94 3.61 16.57 6.95 3.40 9.90 9.90
Price to Tangible BV
2.84 3.09 2.45 2.96 3.63 16.88 6.95 3.63 9.90 9.90
EV/Sales
7.00 67.05 4.33 236.33 8.01 12.43 12.98 2.58 51.64 51.64
EV/EBITDA
0.00 0.00 0.00 0.00 149.45 0.00 0.00 0.00 51.64 51.64
EV/Operating CF
(1.76) (2.45) (17.17) (5.16) 50.07 (17.14) (5.28) (10.64) 0.00 0.00
EV/FCF
(1.75) (2.36) (12.85) (4.71) 132.52 (15.61) (4.20) (6.32) 0.00 0.00
Quick Ratio
2.31 4.29 8.40 9.74 14.60 1.30 1.20 2.70 3.69 1.11
Current Ratio
2.53 4.44 8.62 10.20 14.96 1.68 1.46 3.21 4.56 1.19
Net Debt/EBITDA
0.56 0.75 4.20 1.85 (51.68) 0.68 0.53 1.40 0.26 0.13
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.22% 0.50% 45.28% 1.98%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 1.40 0.06
Asset Turnover
0.16 0.02 0.30 0.01 0.50 0.57 0.24 0.60 0.08 0.01
Operating CF/Net income
0.82 0.85 0.39 0.81 10.55 0.77 0.51 0.19 0.86 0.69
Capex/Depreciation
(0.03) (0.46) (0.80) (1.22) (2.01) (0.79) (2.71) (2.43) (0.43) (0.57)
Interest Coverage
— — — (53.26) 0.30 (164.68) (2.31) (1.95) (54.42) (62.44)
ROE
(117.56%) (79.46%) (23.16%) (43.73%) 0.96% (134.83%) (234.83%) (155.43%) (294.98%) (387.61%)
ROA
(77.90%) (62.87%) (19.53%) (38.04%) 0.76% (53.48%) (114.48%) (74.21%) (98.89%) (129.91%)
ROIC
(5,478.53%) (824.30%) (329.47%) (410.20%) 2.25% (309.13%) (1,543.49%) 0.00% (326.75%) (1,044.57%)
Return on Tangible Assets
(207.46%) (132.87%) (25.47%) (53.70%) 0.53% (131.41%) (285.38%) (98.47%) (99.06%) (529.40%)
Average Days of Receivables
34.48 413.19 13.09 673.85 16.20 63.58 54.95 37.56 77.40 4,714.22
Research and Development Expense of Revenue
345.30% 2,041.75% 95.67% 3,429.77% 48.79% 66.24% 190.42% 77.32% 843.66% 5,731.33%
Selling, General and Administrative Expense of Revenue
203.80% 1,092.43% 54.71% 2,254.52% 37.98% 76.08% 157.72% 74.25% 497.71% 3,772.29%
Intangible Assets out of Total Assets
0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.04 0.05 0.10
Share Based Compensation of Revenue
42.13% 333.79% 17.67% 727.09% 10.21% 27.28% 48.53% 28.60% 297.92% 1,219.28%
Graham Net Nets
0.12 0.19 0.32 0.28 0.24 (0.01) (0.06) 0.21 0.04 0.04
Graham Number
0.00 0.00 0.00 0.00 47.33 0.00 0.00 0.00 45.32 0.00
Earnings Yield
(67.02%) (40.56%) (10.25%) (17.91%) 1.34% (7.80%) (39.81%) (21.37%) 11.28% 11.28%
Free Cash Flow Yield
(55.54%) (35.45%) (5.36%) (15.82%) 0.58% (6.59%) (25.21%) (11.13%) 0.00% 0.00%
Revenue per Share
1.94 0.45 9.62 0.27 15.69 8.91 4.65 11.43 1.81 0.41
Operating CF per Share
(7.72) (12.30) (2.43) (12.42) 2.51 (6.46) (11.44) (2.78) (19.36) (27.26)
Capex per Share
(0.02) (0.42) (0.78) (1.19) (1.56) (0.75) (2.93) (1.90) (0.48) (0.69)
Free Cash Flow per Share
(7.74) (12.72) (3.20) (13.61) 0.95 (7.22) (14.37) (4.67) (19.85) (27.95)
Cash per Share
4.88 10.61 23.63 26.90 43.45 4.86 7.63 12.56 19.29 5.35
Shareholders Equity per Share
4.98 11.76 24.88 29.26 45.26 6.50 8.20 12.36 9.84 7.26
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
4.98 11.76 24.88 29.26 45.26 6.50 8.20 12.36 9.84 7.26
Free Cash Flow
(9.45) (14.57) (3.65) (15.01) 0.95 (4.97) (7.16) (2.05) (5.29) (5.63)
Working Capital
4.08 10.21 24.77 28.55 42.07 2.29 1.58 4.94 5.05 0.36
Capital Expenditures
(0.03) (0.48) (0.89) (1.32) (1.56) (0.52) (1.46) (0.83) (0.13) (0.14)
Net Current Asset Value
2.04 7.94 22.24 26.17 38.98 (0.69) (1.62) 3.84 1.00 (0.34)
EV/EBIT
0.00 0.00 0.00 0.00 1,926.71 0.00 0.00 0.00 51.64 51.64
Capex to Sales
0.01 0.94 0.08 4.40 0.10 0.08 0.63 0.17 0.27 1.67
Price to Operating Income
0.00 0.00 0.00 0.00 2,509.12 0.00 0.00 0.00 54.76 54.76
Other line items
Depreciation/Fixed assets
0.62 0.45 0.40 0.36 0.28 0.31 0.23 0.24 0.29 0.22
Cash ROIC
(78.51%) (56.88%) (6.60%) (24.23%) 1.07% (63.54%) (90.51%) (18.67%) (46.28%) (214.81%)
Accounts Receivable Turnover
5.88 1.06 23.19 0.48 17.74 8.66 5.36 16.23 0.82 0.10
Accounts Payable Turnover
1.13 1.76 1.88 0.37 2.19 3.68 2.58 2.26 0.01 0.00
Inventory Turnover
1.65 2.82 1.86 0.32 1.71 2.79 2.21 3.27 0.09 0.00
Average Days of Payables
266.65 195.42 179.66 1,033.86 188.23 97.03 161.81 136.85 20,513.00 0.00
Days of Inventory on Hand
250.47 98.83 130.89 1,304.88 196.79 153.44 172.50 179.09 4,915.33 0.00
Average Receivables
0.40 0.49 0.47 0.62 0.88 0.71 0.43 0.31 0.59 0.85
Average Payables
0.74 0.93 1.06 1.08 0.92 0.82 0.73 0.73 1.16 1.16
Average Inventory
0.51 0.58 1.07 1.26 1.17 1.08 0.85 0.51 0.17 0.17
Average Assets
14.75 26.42 35.95 44.50 31.03 10.80 9.75 8.42 6.09 6.08
Average Common Equity
9.77 20.90 30.31 38.70 24.80 4.28 4.75 4.02 2.04 2.04

Fold the line items

Columns are period end dates · fundamentals updated 6 Oct 2026